Charles River Laboratories (CRL) Tops Q2 EPS by 16c; Raises Outlook

Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $1.62, $0.16 better than the analyst estimate of $1.46. Revenue for the quarter came in at $585.3 million versus the consensus estimate of $571.33 million.

GUIDANCE:

Charles River Laboratories sees FY2018 EPS of $5.85-$6.00, versus prior of $5.77-$5.92 and the consensus of $5.84. Sees revenue growth of 19-21% versus 18-20%.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.

You May Also Be Interested In

• Morgan Stanley Upgrades Charles River Labs (CRL) to Overweight, 'strong uptick in biopharma funding beginning to transition into RFPs and bookings'
• Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise
• Berenberg Downgrades Umicore SA (UMI:BB) (UMICY) to Hold